Isaac Garcia-Murillas

Scientist at the Molecular Oncology Lab @ICR_London | Epicure | Rock Climber | Balding Father

[Isaac Garcia-Murillas @igmurillas]

Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit sensitivity to PI3Kα inhibitors https://t.co/31XYcnuJfC

[Paolo Tarantino @PTarantinoMD]

Out on @NatureMedicine an interesting review by @LoiSher & colleagues on tumor heterogeneity and its impact on IO efficacy

👉 https://t.co/pBItRpXztt

[Maria Neofytou @MCNeofytou]

The most important genes that increase the risk of Breast Cancer is now published ! #earlydetection #breastcancer
Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women | NEJM https://t.co/xUn8EnbK8O
@CRUKCamEarlyDX

[Alumkal Lab @AlumkalJoshi]

Exciting new paper from the Pritchard Lab @UWMedicine out in @JAMAOnc demonstrates that clonal hematopoiesis #CHIP may confound cfDNA-seq results - particularly for HR DNA repair genes. Clear implications for PARP inhibitor patient selection. https://t.co/rwxLd6NbEA

[Isaac Garcia-Murillas @igmurillas]

https://t.co/9BjU9u8d1Y

[Isaac Garcia-Murillas @igmurillas]

https://t.co/wtuUvfLQ1I

[Isaac Garcia-Murillas @igmurillas]

https://t.co/lErtEnS7G9

[Dr. Ariella Hanker @AriellaHanker]

🙌Tremendous effort from Dr. Kyung-min Lee identifying PRR11 as the gene in the 17q23 amplicon that promotes #antiestrogen resistance in #breastcancer, via activation of #PI3K. @NatureComms Thread 👇
https://t.co/zea7TyrGRw

[Isaac Garcia-Murillas @igmurillas]

https://t.co/vF5yTekiPE

[David Gandara @drgandara]

3 more FDA approvals for molecular testing, this time tumor type-specific: Fast and Furious. FDA Approves FoundationOne®Liquid CDx for Three Targeted Therapies That Treat Advanced Ovarian, Breast and Non-Small Cell Lung Cancer https://t.co/Fpip9M94vi

[Isaac Garcia-Murillas @igmurillas]

https://t.co/l0CqRQXpLT

[Daniel Stover, MD, FASCO @StoverLab]

More data on ctDNA tumor content as a potential biomarker in metastatic #breastcancer.
@MGHCancerCenter @ABhealer108 @JCOPO_ASCO

“Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer”

https://t.co/C0K1G9OadU

[Isaac Garcia-Murillas @igmurillas]

https://t.co/i6Lu3iYofJ

[Isaac Garcia-Murillas @igmurillas]

https://t.co/17INRwZ8lM

[Isaac Garcia-Murillas @igmurillas]

https://t.co/FnhUganf1K

[Mark Dawson @MAF_Dawson]

A pleasure to share our thoughts on a major area of interest for ⁦@TheDawsonLab⁩ ⁦@lab_marine &⁩ others - loved writing it with 2 of my favourite scientists

Non-genetic mechanisms of therapeutic resistance in cancer | Nature Reviews Cancer https://t.co/73r6fXMmNK

[Hunter Shain @ShainLab]

This was one of the most fun and thrilling scientific studies I have ever been a part of. I am so happy to see it published today! What happens to skin cells, specifically melanocytes, as they accumulate sun damage? Read to find out! https://t.co/vw8km8J0hL

[Safia Danovi @SafiaDanovi]

**very cool paper alert**

Somatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure | Nature Genetics https://t.co/jPdccPK8y9

[Razelle Kurzrock, MD @Dr_R_Kurzrock]

Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations for Monitoring Response to Immunotherapy in Cancer Patients | 3 to 8 wks after starting IO for liquid Bx to predict response https://t.co/Ekc77W1QLs

[Kevin Punie @kevinpunie]

@OncoAlert 🚨 Gene expression signatures of #BRCAness +tumor inflammation define subgroups of early #HR+ #breastcancer

🔹#BRCAness independent predictor for shorter EFS
🔹Tumor inflammation signatures ass/w #TILs but not with mutation status
@CCR_AACR

https://t.co/VtorPvWop1